CYPRUMED
CYPRUMED® is a biopharmaceutical company developing a next generation platform technology for the oral delivery of polypeptides. The patent pending technology is entirely based on GRAS listed compounds and easy to formulate. In vivo studies with various polypeptide drugs in rodents, dogs and none human primates showed oral bioavailability up to 70% (rel. s.c.).
CYPRUMED
Industry:
Biotechnology Health Care Medical
Founded:
2015-01-01
Address:
Obsteig, Tirol, Austria
Country:
Austria
Website Url:
http://www.cyprumed.net
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
1000 K EUR
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Apple Mobile Web Clips Icon WordPress Font Awesome Apache Wordpress Plugins
Similar Organizations
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
IntraBio
IntraBio is a biopharmaceutical company.
Current Advisors List
Current Employees Featured
Founder
Official Site Inspections
http://www.cyprumed.net
- Host name: mail.31751-2.whserv.de
- IP address: 89.107.190.180
- Location: Germany
- Latitude: 51.2993
- Longitude: 9.491
- Timezone: Europe/Berlin
More informations about "CYPRUMED"
Oral Peptide Delivery | Cyprumed - Changing biodelivery
Cyprumed is a leading drug delivery company from Austria, specializing in non-invasive administration of biologics and oral peptide delivery. Get in contact!See details»
About us | Cyprumed – Changing biodelivery
Our team of experts and network of specialized service providers with a long experience offer innovative drug delivery solutions. Learn more about our innovative solutions and collaborate with us today!See details»
CYPRUMED - Crunchbase Company Profile & Funding
CYPRUMED® is a biopharmaceutical company developing a next generation platform technology for the oral delivery of polypeptides. The patent pending …See details»
Cyprumed | Drug Discovery News
Apr 24, 2025 Cyprumed Cyprumed is a drug delivery technology company based in Innsbruck, Austria. The company focuses on developing technology platforms for the oral administration …See details»
License and Option Agreement with MSD - cyprumed.net
Apr 15, 2025 Cyprumed will be eligible to receive up to $493 million in upfront, development, regulatory and net sales milestones associated with the approval of any products under the …See details»
CYPRUMED - Company Profile - pharmaservicesdirectory.com
Company Activities Cyprumed is a dedicated drug delivery company based in Innsbruck, Austria. Backed by our team of industry experts, we make therapeutic peptides orally bioavailable. Our …See details»
CYPRUMED Company Profile - Office Locations, Competitors
CYPRUMED has 1 employees at their 1 location. See insights on CYPRUMED including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.See details»
CYPRUMED - VentureRadar
"CYPRUMED is a biopharmaceutical company developing a next generation platform technology for the oral delivery of peptide drugs. CYPRUMED GmbH was established in 2015.See details»
Cyprumed - Overview, News & Similar companies | ZoomInfo.com
View Cyprumed (www.cyprumed.net) location in Tyrol, Austria , revenue, industry and description. Find related and similar companies as well as employees by title and much more.See details»
Life Sciences Directory: Cyprumed GmbH
CYPRUMED GmbH, is an Austrian drug delivery company developing enabling technologies for the non-invasive delivery of biologics, with a focus on oral peptide delivery. Key activities …See details»
Cyprumed: Drug pipelines, Patents, Clinical trials - Synapse
Explore Cyprumed with its drug pipeline, therapeutic area, technology platform, .See details»
Cyprumed Enters License and Option Agreement with MSD for
Apr 15, 2025 Cyprumed will be eligible to receive up to $493 million in upfront, development, regulatory and net sales milestones associated with the approval of any products under the …See details»
News | Cyprumed – Changing biodelivery
Stay informed and up-to-date with the latest news and updates of Cyprumed. Explore our news page today for valuable information and stay connected with us for all the latest updates.See details»
CYPRUMED - Company Information, Competitors, News & FAQs
Find useful insights on CYPRUMED's company details, tech stack, news alerts, competitors and more. Use 6sense to connect with top decision-makers at CYPRUMED.See details»
Cyprumed Enters License and Option Agreement with MSD for the ...
Apr 15, 2025 Cyprumed will be eligible to receive up to $493 million in upfront, development, regulatory and net sales milestones associated with the approval of any products under the …See details»
April, 2025 | Cyprumed – Changing biodelivery
Apr 4, 2025 Cyprumed is a dedicated drug delivery company based in Innsbruck, Austria. Our main focus is the development of proprietary technology platforms for the oral administration of …See details»
Detail - LISA: Advancing Austrian life science
Jan 24, 2022 A combination of Cyprumed´s proprietary oral formulation know-how with compounds approved for use in pharmaceutical products, providing protection against …See details»
Cyprumed Enters License and Option Agreement with MSD for the ...
Apr 15, 2025 Cyprumed will be eligible to receive up to $493 million in upfront, development, regulatory and net sales milestones associated with the approval of any products under the …See details»
Technology | Cyprumed – Changing biodelivery
Cyprumed's technology provides benefits beyond existing delivery systems. We provide three platforms: intestinal and gastric peptide delivery, and an oral BCS IV drug platform. By …See details»
Cyprumed and MSD Partner to Develop Oral Peptide Formulation ...
Apr 17, 2025 Cyprumed will be eligible to receive up to $493 million in upfront, development, regulatory and net sales milestones associated with the approval of any products under the …See details»